Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4611]

AACR 2018: Taking away TIM3 and Tregs stops cancer regrowth after immunotherapy

AACR 2018: Taking away TIM3 and Tregs stops cancer regrowth after immunotherapy

Scientists uncover 80 potential lines of attack against prostate cancer

Scientists uncover 80 potential lines of attack against prostate cancer

AACR 2018: Effect of prostate cancer gene can go either way

AACR 2018: Effect of prostate cancer gene can go either way

AACR 2018: An off-the-shelf, dual-targeted CAR T-cell product showed promising results in preclinical studies

AACR 2018: An off-the-shelf, dual-targeted CAR T-cell product showed promising results in preclinical studies

AACR 2018: Neoadjuvant nivolumab was safe, yielded pathologic responses in patients with resectable lung cancer

AACR 2018: Neoadjuvant nivolumab was safe, yielded pathologic responses in patients with resectable lung cancer

AACR 2018: CheckMate-227 meets co-primary endpoint of PFS in NSCLC

AACR 2018: CheckMate-227 meets co-primary endpoint of PFS in NSCLC

AACR 2018: Boosting T cell “memory” may result in longer-lasting and effective responses for patients treated with checkpoint blockade immunotherapies

AACR 2018: Boosting T cell “memory” may result in longer-lasting and effective responses for patients treated with...

AACR 2018: Updated OS data for olaparib in gBRCA-Mutated HER2 negative metastatic breast cancer

AACR 2018: Updated OS data for olaparib in gBRCA-Mutated HER2 negative metastatic breast cancer

AACR 2018: New liquid biopsy-based cancer model reveals data on deadly lung cancer

AACR 2018: New liquid biopsy-based cancer model reveals data on deadly lung cancer

AACR 2018: First-in-human clinical trial of new targeted therapy drug reports promising responses for multiple cancers

AACR 2018: First-in-human clinical trial of new targeted therapy drug reports promising responses for multiple...

More from ecancer